Travere Therapeutics broadened its rare kidney portfolio by exclusively licensing civorebrutinib from Everest Medicines in a deal potentially worth more than $1.14 billion. The agreement adds development and commercialization rights across all markets outside China and certain East and Southeast Asian countries. Travere will pay $112.5 million upfront to Everest, with the biotech eligible to receive up to $1.03 billion in additional milestones plus royalties. Initial efforts will focus on primary membranous nephropathy, after Everest generated proof-of-concept data for the target. The transaction comes shortly after Travere secured FDA approval for a second indication for Filspari (sparsentan), highlighting a continued push to build adjacency in immune-mediated kidney diseases. For patients and clinicians, the move signals potential diversification of mechanistically distinct options in a space that has increasingly emphasized targeted immunology approaches rather than purely symptomatic management.